The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

• Main Authors: Chiara Tarantelli (Author), Eleonora Cannas (Author), Hillarie Ekeh (Author), Carmelo Moscatello (Author), Eugenio Gaudio (Author), Luciano Cascione (Author), Sara Napoli (Author), Cesare Rech (Author), Andrea Testa (Author), Chiara Maniaci (Author), Andrea Rinaldi (Author), Emanuele Zucca (Author), Anastasios Stathis (Author), Alessio Ciulli (Author), Francesco Bertoni (Author)
• Format: Book
• Published: Open Exploration Publishing Inc., 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targeting as an anti-cancer approach. BET degraders are chimeric compounds comprising of a BET inhibitor, whi...